Galderma will share a host of clinical and patient satisfaction data on its portfolio of products at the AMWC in Monaco.
Galderma will present new clinical data on their hyaluronic acid dermal filler range, their first liquid neuromodulator, and their original collagen biostimulator at the Aesthetic and Anti-Aging Medicine World Congress (AMWC) taking place in Monaco and virtually from March 31 to April 2.
Dr Philippe Kestemont will present an overview of clinical data for Alluzience, Galderma’s recently approved and Europe’s first ready-to-use liquid neuromodulator to treat moderate to severe glabellar lines.
Pooled data from two Phase III studies show that Alluzience successfully improved glabellar lines regardless of severity with rapid onset and results lasting up to 6 months. Improvements in GL severity, satisfaction, and psychological wellbeing were also consistent over several treatment cycles with Alluzience.
The latest long-lasting efficacy and safety results will also be presented on the new formulation of Sculptra, a poly-L-lactic acid (PLLA) approved by the FDA.
The new formulation means it can be reconstituted to 5ml or 8ml, used immediately, and an optional 1mL of lidocaine can be added for patient comfort. The open-label extension study evaluating the new formulation of 8mL showed Sculptra was well tolerated and had a long-lasting duration of effect, with subject satisfaction up to 96 weeks.
Galderma will also present data demonstrating the effectiveness and high patient satisfaction in patients treated with hyaluronic acid fillers. The Andreas Nikolis, MD, CHEEKY post-market study evaluated treatment with Restylane Lyft for those needing a projection effect and Restylane Volyme for a contouring/volumizing effect.
In addition, Steven Dayan, MD, FCAS, will detail positive results from a post-marketing study evaluating facial harmony and patient satisfaction after treatment with Restylane Defyne, a flexible hyaluronic acid filler, using a stepwise treatment approach.
Finally, at AMWC, Galderma will be hosting a symposium that has been developed with some of the world’s most talented aesthetic physicians. Titled ‘A New Patient-Centric Approach to turn your AART into a HIT, the Galderma symposium will focus on using AART – Anatomy, Assessment, Regimen, and Therapy – to deliver a Holistic Individualized Treatment (HIT) for each patient.
Moderated by Nikolis, the symposium will feature interactive sessions with Sebastian Cotofana, Kay Durairaj, Christoph Martschin, Marcus Morais, and Frank Rosengaus, as well as live injections and a panel assessment.
Photo 155343423 © Ammentorp | Dreamstime.com
